Clinical Trials
28
Active:2
Completed:8
Trial Phases
3 Phases
Phase 1:21
Phase 2:6
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (28 trials with phase data)• Click on a phase to view related trials
Phase 1
21 (75.0%)Phase 2
6 (21.4%)Phase 3
1 (3.6%)A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABSK061 Mini-tablets in Healthy Adult Participants
- First Posted Date
- 2025-06-06
- Last Posted Date
- 2025-06-06
- Lead Sponsor
- Abbisko Therapeutics Co, Ltd
- Target Recruit Count
- 42
- Registration Number
- NCT07007546
- Locations
- 🇨🇳
Jiangnan University Affiliated Hospital, Wuxi, Jiangsu, China
A Mass Balance Study of [14C]ABSK011
Phase 1
Not yet recruiting
- Conditions
- Healthy Subjects
- Interventions
- Drug: [14C]ABSK011
- First Posted Date
- 2025-03-26
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- Abbisko Therapeutics Co, Ltd
- Target Recruit Count
- 6
- Registration Number
- NCT06896760
- Locations
- 🇨🇳
Beijing GoBroad Hospital, Beijing, Beijing, China
A Study to Evaluate the Effect of a High-fat Meal on the Exposure of Pimicotinib Capsule in Healthy Subjects
Phase 1
Active, not recruiting
- Conditions
- Healthy Subjects
- Interventions
- Drug: Pimicotinib capsule
- First Posted Date
- 2025-03-19
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- Abbisko Therapeutics Co, Ltd
- Target Recruit Count
- 16
- Registration Number
- NCT06884072
- Locations
- 🇨🇳
The First Hospital of Jilin University, Changchun, Jilin, China
A Study to Investigate The Effect of Pimicotinib on The Pharmacokinetics of Metformin, Fexofenadine and Rosuvastatin In Healthy Subjects
- First Posted Date
- 2025-01-16
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Abbisko Therapeutics Co, Ltd
- Target Recruit Count
- 39
- Registration Number
- NCT06779253
- Locations
- 🇨🇳
The First Affiliated Hospital Shandong First Medical University (Shandong Provincial Qianfoshan Hospital), Jinan, Shandong, China
A Study to Evaluate the Relative Bioavailability of Two Different Pimicotinib Capsules in Healthy Subjects
- First Posted Date
- 2024-11-19
- Last Posted Date
- 2025-02-17
- Lead Sponsor
- Abbisko Therapeutics Co, Ltd
- Target Recruit Count
- 26
- Registration Number
- NCT06694948
- Locations
- 🇨🇳
The First Hospital of Jilin University, Changchun, Jilin, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- Next
News
No news found